Kirk Ways, an executive at Aventis Pharmaceuticals, is the new vice president and chief development officer at BioStratum.

Ways, an MD and PhD, was senior global medical director and global project team leader at Aventis. He also was a research advisor at Eli Lilly, with an emphasis on diabetes, and director of the diabetes center at East Carolina University.

“To have an individual of Dr. Ways’ stature join the BioStratum team will be immensely valuable,” said Dr. Robert Schotzinger, president and chief executive officer of BioStratum, in a statement. “His skills in clinical development as well as breadth of knowledge related to all aspects of pharmaceutical development will be an invaluable asset to us as we continue to grow.”

Ways will be responsible for drug development efforts at BioStratum, including a treatment in Phase II trials for diabetic kidney disease.